Compartir
array:19 [ "pii" => "13143259" "issn" => "02104806" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:584-92" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2411 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 1403 "PDF" => 1002 ] ] "itemSiguiente" => array:14 [ "pii" => "13143258" "issn" => "02104806" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:593-602" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2181 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 1398 "PDF" => 777 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Tratamiento quirúrgico de las metástasis del cáncer renal" "tienePdf" => array:2 [ 0 => "es" 1 => "en" ] "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "593" "paginaFinal" => "602" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:2 [ "es" => true "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José L. Ruiz-Cerdá, Fernando Jiménez Cruz" "autores" => array:2 [ 0 => array:2 [ "nombre" => "José L." "apellidos" => "Ruiz-Cerdá" ] 1 => array:2 [ "nombre" => "Fernando" "apellidos" => "Jiménez Cruz" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13143258?idApp=UINPBA00004N" "url" => "/02104806/0000003300000005/v0_201607111116/13143258/v0_201607111120/es/main.assets" ] "itemAnterior" => array:14 [ "pii" => "13143260" "issn" => "02104806" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "documento" => "article" "subdocumento" => "fla" "cita" => "Actas Urol Esp. 2009;33:575-83" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2464 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 1630 "PDF" => 827 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Factores pronósticos del carcinoma de células renales" "tienePdf" => array:2 [ 0 => "es" 1 => "en" ] "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "575" "paginaFinal" => "583" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:2 [ "es" => true "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rafael A. Medina López, José M. Conde Sánchez, Carmen B. Congregado Ruiz, Raquel González Resina, Salvador Mármol Navarro, Francisco J. Torrubia Romero" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Rafael A." "apellidos" => "Medina López" ] 1 => array:2 [ "nombre" => "José M." "apellidos" => "Conde Sánchez" ] 2 => array:2 [ "nombre" => "Carmen B." "apellidos" => "Congregado Ruiz" ] 3 => array:2 [ "nombre" => "Raquel" "apellidos" => "González Resina" ] 4 => array:2 [ "nombre" => "Salvador" "apellidos" => "Mármol Navarro" ] 5 => array:2 [ "nombre" => "Francisco J." "apellidos" => "Torrubia Romero" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13143260?idApp=UINPBA00004N" "url" => "/02104806/0000003300000005/v0_201607111116/13143260/v0_201607111119/es/main.assets" ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Tratamiento del cáncer renal metastásico: vigencia de lainmunoterapia" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "584" "paginaFinal" => "592" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Roberto Llarena Ibarguren" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Roberto" "apellidos" => "Llarena Ibarguren" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Servicio de Urología. Hospital de Cruces. Baracaldo, Vizcaya. España" "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "pdfFichero" => "292v33n05a13143259pdf001.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec689508" "palabras" => array:4 [ 0 => "Inmunoterapia" 1 => "Citocinas" 2 => "Interferon" 3 => "Interleukina" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec689509" "palabras" => array:4 [ 0 => "Immunotherapy" 1 => "Cytokines" 2 => "Interferon" 3 => "Interleukin" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "Objetivo: Evaluar la importancia y efectos de la inmunoterapia clásica en el tratamiento del cáncer renal diseminado.Material y métodos. Se revisan los datos históricos de los estudios realizados con citocinas, interferon e interleukina, evaluandosus combinaciones, y comparando los diferentes estudios relevantes existentes. <br />Comentarios: Aunque diversos, los resultados son pobres en cuanto a respuesta objetivable y en cuanto a duración de lamisma, observando series ya históricas que empleando interleukina2 lograron, pesar de graves efectos secundarios, remisionesincluso completas de la enfermedad. <br />Conclusiones: En la actualidad y tras el advenimiento de los nuevos fármacos, el empleo de la inmunoterapia clásica puedeencontrar indicación en pacientes concretos, con buen estado general, con nefrectomía previa por carcinoma de células claras,al menos 12 meses antes de la aparición de metástasis en un solo órgano, preferentemente pulmón, y con niveles normales dehemoglobina, calcio y lactodehidrogenasa, buscando ese pequeño porcentaje de respuestas estables y mantenidas." ] "en" => array:1 [ "resumen" => "Objective: To assess the significance and effects of conventional immunotherapy for management of disseminated renalcancer. <br />Materials and methods: Historical data from studies conducted with cytokines, interferon, and interleukin are reviewed,their combinations are evaluated, and the different relevant studies available are compared. <br />Discussion: While diverse, results are poor in terms of objective response and its duration. Historical series usinginterleukin-2 achieved, despite severe side effects, disease remissions, some of them complete. <br />Conclusions: Currently, after the advent of new drugs, use of conventional immunotherapy may be indicated for specificpatients with a good general condition undergoing previous nephrectomy for a clear cell carcinoma at least 12 monthsbefore occurrence of metastasis in a single organ, preferably the lung, and with normal levels of hemoglobin, calcium, andlactate dehydrogenase, looking for that small percentage of stable and sustained responses." ] ] ] "idiomaDefecto" => "es" "url" => "/02104806/0000003300000005/v0_201607111116/13143259/v0_201607111120/es/main.assets" "Apartado" => array:4 [ "identificador" => "55588" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Original" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02104806/0000003300000005/v0_201607111116/13143259/v0_201607111120/es/292v33n05a13143259pdf001.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13143259?idApp=UINPBA00004N" "pdfAlternativo" => array:1 [ 0 => array:3 [ "idioma" => "en" "documentoPdf" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/file/02104806/addon/13143259/S300/en/292v33n05a13143259pdf001_2.pdf" "portada" => "292v33n05a13143259pdf001_2.png" ] ] ]
